Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study (SNOW)

Trial Profile

Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study (SNOW)

Status: Recruiting
Phase of Trial: Phase 0

Latest Information Update: 09 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Sitravatinib (Primary)
  • Indications Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
  • Focus Biomarker; Pharmacodynamics; Proof of concept
  • Acronyms SNOW
  • Most Recent Events

    • 09 Nov 2019 Preliminary results presented in the Mirati Therapeutics media release.
    • 09 Nov 2019 According to a Mirati Therapeutics media release, preliminary results (data cut-off date of October 9, 2019) from the trial were presented in an oral presentation at the Society of Immunotherapy of Cancer (SITC) 34th Annual Meeting in National Harbor, MD.
    • 23 Oct 2019 According to a Mirati Therapeutics media release, data from this study will be presented at the ociety for Immunotherapy of Cancer (SITC) 34th Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top